ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells
Håkan Mellstedt(Karolinska University Hospital), Hodjattallah Rabbani(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Ladan Mansouri(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital)
Cited by 3
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312